MedTrace Logo

Study of the Inappropriate Secretion of FGF23 in Patients Followed in Hospital in a Context of Hypophosphatemia

NCT04846647 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 260

Last updated 2023-05-11

No results posted yet for this study

Summary

The discovery of FGF23, the missing link in the long researched and finally found phosphate metabolism, marked a turning point in the understanding and physiopathology of specific hypophosphatemia. By inhibiting the renal reabsorption of phosphate and the production of calcitriol, FGF23 behaves like a hypophosphatemia hormone.

Hypersecretion of FGF23 can occur in the case of genetic abnormalities (X-linked hypophosphatemic vitamin-resistant rickets, recessive or dominant hypophosphatemic rickets, McCune-Albright syndrome ...) or acquired abnormalities (oncogenic osteomalacia). Oncogenic osteomalacia can be induced by hyperproduction of FGF23 by benign tumours of mesenchymal origin. But more recently, several cases of malignant tumours secreting FGF23 have also been described (prostate, colon, breast, ovarian and lung cancers, pulmonary carcinoma, etc.)

Conditions

  • Hypophosphatemia Without Immediate Anteriority
  • Unexplained Hypophosphatemia

Interventions

BEHAVIORAL

unexplained hypophoshatemia

Collection of additional blood volume (approximately 10 mL) during blood tests provided as part of the usual medical care.

Sponsors & Collaborators

  • DiaSorin ; Saluggia, Italia

    collaborator UNKNOWN

  • University Hospital, Clermont-Ferrand

    lead OTHER

Principal Investigators

  • Damien BOUVIER · University Hospital, Clermont-Ferrand

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-05
Primary Completion
2022-04-25
Completion
2022-04-25

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04846647 on ClinicalTrials.gov